Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
BiotechTV - News
00:00
High-dose Q12-week efficacy details
Rand details 100 mg every 12 weeks producing 56% exacerbation reduction and improvements in FEV1 and FeNO.
Play episode from 02:23
Transcript
